Expensify, Inc.
NASDAQ:EXFYSoftware - Application
+$0.35 today
- Market cap
- $157.19M
- Beta
- 1.80
- P/E (TTM)
- -7.0
- EPS (TTM)
- -$0.22
Volume 0.63M
Average 0.79M
EXFY Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Expensify, Inc.NASDAQ: EXFY
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $6.27M rose 418.8% year over year, ahead of the +110.7% change in trailing-twelve-month financing cash flow. Over 3 fiscal years it compounded at -30.8% a year.
Context
- Financing cash flow amounted to 1.9% of revenue in FY2025, down 13.9 pp from a year earlier.
- Financing cash flow grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +418.8% holds above the trailing-twelve-month pace of +110.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (2.74M) USD
- Year-over-year change
- +87.6%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.74M) | +87.6% |
| FY2024 | 2024-12-31 | (22.07M) | +51.3% |
| FY2023 | 2023-12-31 | (45.32M) | -447.2% |
| FY2022 | 2022-12-31 | (8.28M) | -110.3% |
| FY2021 | 2021-12-31 | 80.57M | — |
Financing Cash Flow vs competitors
How EXFY compares with its peers on the latest reported figures
- EXFY's LTM Mar 2026 financing cash flow of $2.32M is the 8th largest of the 10 companies compared; the peer median is $6.25M.
- Its year-over-year change of +110.7% is the 2nd highest of 9, against a peer median of -41.3%.
- Financing cash flow amounts to 1.7% of revenue for EXFY, versus a peer median of 10.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $72.95M | -35.5% | +88.7% | 392.9% | |
TEADTeads Holding Co. | LTM Mar 2026 | $41.86M | -108.7% | — | 3.3% |
| LTM Mar 2026 | $25.94M | -45.9% | +31.2% | 7.2% | |
| LTM Mar 2026 | $19.25M | — | — | 10.7% | |
| LTM Mar 2026 | $8.86M | -36.7% | +64.8% | 54.8% | |
| FY2025 | $7.15M | +1961.2% | — | 41.8% | |
HITHealth In Tech, Inc. | LTM Mar 2026 | $6.25M | +47.4% | — | 18.3% |
| LTM Mar 2026 | $2.32M | +110.7% | -30.8% | 1.7% | |
SVCOSilvaco Group, Inc. Common Stock | LTM Mar 2026 | $1.98M | -98.0% | — | 3.0% |
| LTM Mar 2026 | $1.84M | -78.9% | +10.4% | 1.8% | |
| Peer median (excluding EXFY) | $6.25M | -41.3% | +48.0% | 10.7% | |
Competitors are the stored peer set for EXFY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (13.56M) | (27.01M) | (41.46M) | (10.06M) | (21.39M) |
| Depreciation & Amortization | 5.2M | 5.39M | 5.16M | 6.81M | 8.46M |
| Deferred Income Tax | (868K) | 26K | (113K) | (42K) | 5K |
| Stock-Based Compensation | 14.57M | 52.33M | 41.21M | 33.54M | 26.58M |
| Change in Working Capital | (951K) | 550K | (5.04M) | (7.71M) | 5.12M |
| Accounts Receivables | (5.42M) | (1.34M) | 2.22M | 704K | (355K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.42M | (2.69M) | 228K | (1.09M) | 91K |
| Other Working Capital | 3.05M | 4.58M | (7.49M) | (7.32M) | 5.39M |
| Other Non-Cash Items | 1.09M | 1.59M | 1.79M | 1.33M | 1.31M |
| Operating Cash Flow | 5.49M | 32.88M | 1.56M | 23.88M | 20.09M |
| Capital Expenditures | (7.61M) | (2.2M) | (7.29M) | (7.63M) | (17K) |
| Acquisitions (Net) | 0 | 5K | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (4.91M) | 0 | (5.91M) | 0 | (3.54M) |
| Investing Cash Flow | (7.61M) | (2.2M) | (7.29M) | (7.63M) | (3.56M) |
| Debt Repayment | 19.04M | (1.39M) | (45.1M) | (22.8M) | (140K) |
| Common Stock Issued | 58.03M | 3.67M | 4.26M | 4.09M | 6.64M |
| Common Stock Repurchased | 0 | (6.03M) | (3.02M) | (1.55M) | (9.1M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 3.51M | (5.34M) | (1.46M) | (1.82M) | (153K) |
| Financing Cash Flow | 80.57M | (8.28M) | (45.32M) | (22.07M) | (2.74M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 78.44M | 22.4M | (51.05M) | (5.82M) | 13.79M |
| Free Cash Flow | (2.13M) | 30.67M | (5.74M) | 16.25M | 20.07M |
Expensify, Inc.
NASDAQ:EXFY
Intrinsic Alpha fair value
Locked
Current Price
$1.63
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.